New Analyst Forecast: $MDWD Given 'Buy' Rating

H.C. Wainwright initiated coverage of $MDWD with a 'Buy' rating. Recent institutional investor activity in Q1 2025 shows mixed sentiment, with 33 institutions increasing their positions, including PRICE T ROWE ASSOCIATES INC adding 159,691 shares, while 28 decreased their holdings; notable reductions came from ROSALIND ADVISORS, INC., WELLS FARGO & COMPANY/MN and others.

Analysis

MediWound Ltd. ($MDWD) has received a new 'Buy' rating from H.C. Wainwright as of May 22, 2025, contributing to a current Wall Street consensus where one firm issues a buy rating and no firms issue sell ratings. This analyst action contrasts with recent institutional investor activity in Q1 2025, which presents a mixed picture. While 33 institutional investors added $MDWD shares to their portfolios, a notable new position was established by PRICE T ROWE ASSOCIATES INC, acquiring 159,691 shares valued at approximately $2.48 million. Conversely, 28 institutions reduced their holdings. Significant divestitures include ROSALIND ADVISORS, INC. reducing its stake by 121,157 shares (-19.3%) valued at $1.88 million, WELLS FARGO & COMPANY/MN cutting its position by 75,208 shares (-84.1%) valued at $1.17 million, and PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. completely divesting its 37,760 shares. Other notable reductions came from BALYASNY ASSET MANAGEMENT L.P. (-36.3%), SARGENT INVESTMENT GROUP, LLC (-43.3%), and J. GOLDMAN & CO LP (-77.8%). The overall sentiment, as per provided signals, is mildly positive (score 0.3) with a moderate market impact score (0.35), reflecting this divergence between analyst outlook and some institutional repositioning.

Key Decisions for Investors

• Investors should acknowledge the positive catalyst from H.C. Wainwright's 'Buy' rating on $MDWD, but weigh it against the mixed institutional flows observed in Q1 2025.
• Detailed due diligence is warranted to understand the rationale behind significant institutional sales by firms like Rosalind Advisors and Wells Fargo, especially in contrast to new large purchases like that of Price T Rowe Associates.
• Monitor upcoming institutional holding reports and any further analyst rating changes to better assess the evolving conviction around $MDWD's prospects.